Brazil's Bio-Manguinhos Institute Still in Bidding Process for Oxford's COVID-19 Vaccine Production, an Industrial Info Market Brief

The Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos (Institute of Technology in Immunobiology Bio-Manguinhos) has just started the bidding process for its $127 million project for fill and finish production of Oxford's COVID-19 vaccine. The vaccine is still in the clinical human trials stage, but conclusive results are expected before the end of the year.